Short answer: the calculator above gives a calculated estimate of parenteral nutrition (PN, “TPN”) osmolarity in mOsm/L. Estimates like this multiply each component’s concentration in the final admixture by a per-gram or per-mEq factor and add the results. This page explains where those factors come from, how to check the arithmetic by hand, and how to read the result against the commonly used 900 mOsm/L peripheral threshold. That threshold is a weakly graded convention, not a proven safety line. ASPEN’s 2014 guideline grades it Weak, and institutional thresholds vary [1].
Calculated vs measured. Every PN number on this page is a calculated estimate (mOsm/L) unless it is marked “measured”. Measured osmolality (mOsm/kg, by osmometer) of real PN solutions can differ from the estimate by tens of mOsm in either direction [2]. See Osmolality vs Osmolarity.
1. The estimating equation
Osm (mOsm/L) ≈ AA (g/L) × f_AA + dextrose (g/L) × 5.046 + lipid (g/L) × f_lipid + Σ (electrolyte mEq/L × factor)
f_AA is the selected amino-acid product’s label value; when no product is specified, the generic teaching value of 10 mOsm/g is used and labelled as generic.
The component list follows an ASHP 2016 PN-order-writing program, which cites Mattox in Pharmacotherapy: A Pathophysiologic Approach (9e) [3]. Where a product label allows it, the factor is the label’s calculated osmolarity divided by the label quantity, and the label value governs. For calcium gluconate, the only US label that prints a value matches measured osmolality rather than a calculated value, so this page uses the calculated (“theoretical”) value from a UK label as an editorial default. The sources conflict; see the calcium gluconate note.
| Component | Factor | Check |
|---|---|---|
| Amino acids | Product-specific label value (US labels: 7.88–9.98 mOsm/g). Generic fallback 10 mOsm/g when no product is specified | Travasol 10% 998 ÷ 100 = 9.98; Prosol 20% 1835 ÷ 200 = 9.175; Aminosyn-PF 10% 788 ÷ 100 = 7.88 [7, 8, 22]. 10 is the ASHP/Mattox teaching value [3] and is at or above every US label checked |
| Dextrose (hydrous) | 5.046 mOsm/g | ICU Medical Dextrose 50% label: 2523 mOsm/L (calc) ÷ 500 g/L = 5.046 [20]. Labels that print a rounded figure give slightly different quotients (D5W 252 ÷ 50 = 5.04 [4]); these are rounding differences |
| Lipid, 20% emulsion | 1.3 mOsm/g fat (ASHP table: 1.3–1.5) | Intralipid 20%: 260 mOsm/L ÷ 200 g/L = 1.30 [5]. Intralipid-specific; other 20% emulsions have their own label osmolarities |
| Lipid, 30% emulsion | 0.6667 mOsm/g fat | Intralipid 30%: 200 mOsm/L ÷ 300 g/L = 0.6667 [6] |
| Na⁺ or K⁺ as chloride or acetate | 2 mOsm/mEq (cation + anion) | Hospira labels: NaCl 14.6% 5 mOsm/mL ÷ 2.5 mEq/mL = 2.0; KCl 4 ÷ 2 = 2.0; Na acetate 4 ÷ 2 = 2.0; K acetate 4 ÷ 2 = 2.0 mOsm/mEq [14–17] |
| Sodium phosphate | ≈1.75 mOsm/mEq Na (label: 7 mOsm/mL calc ÷ 4 mEq Na/mL) | Hospira Sodium Phosphates Injection [9]. Some teaching tables list 3 mOsm/mEq Na [3]; that does not match current US labeling |
| Potassium phosphate | 1.6818 mOsm/mEq K (≈1.68; label: 7.4 mOsm/mL calc ÷ 4.4 mEq K/mL) | Potassium Phosphates Injection labels from Hospira [19] and American Regent [10] print the same values. Teaching tables give 1.7–2.7 depending on salt mix and pH [3]; other products may differ, so state the factor you use |
| Magnesium sulfate | 1.0 mOsm/mEq | Hospira MgSO₄ 50% label: 4.06 mOsm/mL (calc.) ÷ 4.06 mEq/mL = 1.0 [18] |
| Calcium gluconate | 1.4667 mOsm/mEq Ca: editorial default, calculated from a UK label’s theoretical osmolarity; sources conflict (label figures give 1.4348–1.4798, or 0.628 from one US label), see note. It has not been reviewed by a clinician. | Label-derived calculated value: B. Braun UK SmPC ‘Theoretical osmolarity: 660 mOsm/l’ at 2.25 mmol Ca/10 mL (= 450 mEq/L) → 1.4667 [23]; Sandoz Canada lists 680 mOsmol/L at 0.465 mEq/mL (≈1.46), without stating whether this is calculated or measured [24]. One US label (B. Braun pharmacy bulk package) prints 292 mOsmol/L (calc.) (≈0.63/mEq) [21], close to the measured osmolality of 10% calcium gluconate (270–310 mOsmol/kg [25]) and not used here. The hameln label states that its product “should not be used in the preparation of Total Parenteral Nutrition (TPN), due to the risk of exposure to aluminium”. It is cited here only for its measured osmolality. |
Calcium gluconate: the sources conflict. This calculator uses 1.4667 mOsm per mEq of calcium as an editorial default. It is calculated from a UK label (B. Braun, Calcium Gluconate 10% w/v Injection BP) [23]: “Theoretical osmolarity: 660 mOsm/l” with 2.25 mmol of calcium per 10 mL (450 mEq/L), so 660 ÷ 450 = 1.4667. Other figures exist:
- The same label also states the calcium content as 0.23 mmol per mL; using that rounded figure would give 1.4348. Its warnings section states 2.23 mmol per 10 mL, which would give 1.4798. Osmolar uses the 2.25 mmol figure from the composition section. [23]
- A Canadian label (Sandoz) lists 680 mOsmol/L at 0.465 mEq/mL (1.4624) and does not say whether this is calculated or measured. [24]
- A US label (B. Braun pharmacy bulk package) lists “Osmolarity (Calc.): 292 mOsmol/L” (0.628 per mEq) [21]. That figure is close to the measured osmolality of 10% calcium gluconate (270–310 mOsmol/kg on another UK label) [25] and would give a lower estimate, so it is shown here but not used.
We use 1.4667 because it is a calculated value, like every other factor in this calculator. This choice has not been reviewed by a clinician or pharmacist. For 9.2 mEq of calcium per litre, 1.4667 adds 13.5 mOsm/L and 0.628 adds 5.8 mOsm/L. The difference matters most when an estimate is close to 900 mOsm/L.
Three rules keep the estimate honest:
- Work per liter of final admixture. Divide bag totals by the final volume first.
- The lipid factor depends on emulsion strength. Most of an emulsion’s osmolarity comes from its glycerin rather than the fat: Intralipid 20% contains 2.25 g glycerin per 100 mL (22.5 g/L ÷ 92.09 g/mol ≈ 244 mOsm/L, about 94% of the labelled 260), and Intralipid 30% contains 1.7 g/100 mL (≈185 of 200 mOsm/L, about 92%) [5, 6]. This is our arithmetic from the label composition, assuming ideal behaviour. When people say “lipid lowers PN osmolarity”, they mean dilution: lipid adds volume while adding few mOsm.
- It is an estimate. Valero Zanuy et al. measured 12 PN solutions by freezing-point osmometry. Published equations generally underestimated measured osmolality, but the ASPEN Safe Practices (2004) equation overestimated it for peripheral PN [2]. Where it matters, measure.
Neonatal PN behaves differently (for example, Pereira-da-Silva’s neonatal equation includes phosphorus and a constant [11]). This page does not cover neonatal thresholds.
2. The peripheral threshold: what “900 mOsm/L” does and doesn’t mean
ASPEN 2014 (Boullata et al.), Question 2, recommendation, verbatim: “We suggest that PN with an osmolarity of up to 900 mOsm/L can be safely infused peripherally. Higher osmolarity limits, especially when peripheral PN is prepared as a total nutrient admixture (TNA), may also be tolerated, but the evidence to support a safe limit is lacking.” GRADE: Weak [1].
How to read this:
- The grade is Weak, and the evidence base is small observational studies and small trials [1]. ASPEN’s evidence summary states that the osmolarity of the peripheral PN regimens evaluated ranged from about 400 to 1700 mOsm/L, and that the rate of infusion was often not controlled or described [1]. Treat 900 mOsm/L as a commonly used convention, not as a line that separates safe from unsafe.
- Product labels set it as a hard rule. Intralipid labels state that admixtures ≥900 mOsm/L must be infused through a central vein, and that <900 mOsm/L may be given centrally or peripherally [5, 6].
- Amino-acid labels add a second criterion. The Travasol and Prosol labels state: “Solutions with greater than 5% dextrose or with osmolarity of 900 mOsm/L or greater must be infused through a central venous catheter” [7, 8].
- Other thresholds exist. An ASHP program citing the ASPEN core curricula gives 900–1000 mOsm/L as the adult/pediatric peripheral maximum [3]. In a pediatric cohort, PPN above 1000 mOsm/L was associated with more infiltration and phlebitis than ≤1000 [12].
- Osmolarity rate matters too. Timmer and Schipper found that phlebitis correlated poorly with osmolarity alone (r = 0.37) but well with the mOsm infused per hour (r = 0.95) [13]. ASPEN notes that osmolarity rates <100 mOsm/h improve patient tolerance [1].
- Peripheral PN still causes phlebitis below 900. In Timmer’s study, a mixture of 829 mOsm/L still had a 14% phlebitis rate by day 14 [13].
How osmolar.com phrases results: “estimated X mOsm/L, which is above (≥900) or below (<900) the commonly used 900 mOsm/L peripheral threshold. Estimate only. Institutional thresholds vary. Verify with your pharmacist.” We do not label any value “safe”.
Estimate only. The estimate can differ from the measured value by tens of mOsm/L in either direction, so a value near 900 can fall on either side [2]. Route decisions follow the prescriber, the pharmacist and local policy; this calculator does not choose a route.
3. Worked examples
All results are calculated estimates in mOsm/L of final admixture.
Example 1: PN estimate with a 20% lipid emulsion
Per liter of final admixture: amino acids 30 g (product not specified, so the generic factor 10 is used), dextrose 50 g, fat 30 g (from 20% emulsion), Na⁺ 50 mEq (as NaCl), K⁺ 20 mEq (as KCl), Mg²⁺ 5 mEq (as sulfate), Ca²⁺ 5 mEq (as gluconate).
| Component | Arithmetic | mOsm/L |
|---|---|---|
| Amino acids | 30 × 10 | 300 |
| Dextrose | 50 × 5.046 | 252.3 |
| Lipid (20%) | 30 × 1.3 | 39 |
| NaCl | 50 × 2 | 100 |
| KCl | 20 × 2 | 40 |
| MgSO₄ | 5 × 1 | 5 |
| Ca gluconate | 5 × 1.4667 | 7.3335 |
| Total | 300 + 252.3 + 39 + 100 + 40 + 5 + 7.3335 | 743.6335 ≈ 744 |
Result: estimated 744 mOsm/L, which is below the commonly used 900 mOsm/L peripheral threshold. This is an estimate only, and institutional thresholds vary.
Variant (30% emulsion): lipid = 30 × 0.6667 = 20.001, so total = 300 + 252.3 + 20.001 + 100 + 40 + 5 + 7.3335 = 724.6345 ≈ 725 mOsm/L.
Variant (named amino-acid product): with Travasol 10% (9.98 mOsm/g), AA = 30 × 9.98 = 299.4, total = 743.0335 ≈ 743. With Aminosyn-PF 10% (7.88 mOsm/g), AA = 30 × 7.88 = 236.4, total = 680.0335 ≈ 680, about 64 lower than the generic result (743.6335 − 680.0335 = 63.6) [7, 22].
Example 2: Normalizing a bag to per-liter
A 2 L bag contains 100 g amino acids, 400 g dextrose, Na⁺ 120 mEq (NaCl), K⁺ 80 mEq (KCl), Mg²⁺ 20 mEq (sulfate), Ca²⁺ 18.4 mEq (gluconate). No lipid.
Step 1. Per liter. Divide everything by 2: AA 50 g, dextrose 200 g, Na⁺ 60, K⁺ 40, Mg²⁺ 10, Ca²⁺ 9.2 mEq. Step 2. Apply the factors. 50 × 10 (generic AA) = 500. 200 × 5.046 = 1009.2. 60 × 2 = 120. 40 × 2 = 80. 10 × 1 = 10. 9.2 × 1.4667 = 13.49364. Step 3. Sum. 500 + 1009.2 + 120 + 80 + 10 + 13.49364 = 1732.69364 ≈ 1733 mOsm/L. Result: the estimate is above the commonly used 900 mOsm/L threshold. Product labeling states that admixtures ≥900 mOsm/L must be infused through a central vein [5]. Estimate only. Route decisions follow your institution’s protocol and pharmacist. Trap: entering the bag totals without dividing by volume gives 3465.38728 ≈ 3465, double the true value.
Example 3: Near the 900 line
Per liter: AA 35 g (generic factor 10), dextrose 100 g, Na⁺ 23 mEq (as NaCl).
Step 1. 35 × 10 = 350. 100 × 5.046 = 504.6. 23 × 2 = 46. Step 2. 350 + 504.6 + 46 = 900.6 ≈ 901 mOsm/L, in the ≥900 category. Dextrose-factor trap: with the old round factor of 5, dextrose = 500 and the total is 350 + 500 + 46 = 896, which would fall below 900. Near the line, the third significant figure of a factor matters.
Variant (display boundary): with Na⁺ 22.5 mEq instead, NaCl = 22.5 × 2 = 45, and the total is 350 + 504.6 + 45 = 899.6, which displays as 900. osmolar.com classifies on the displayed whole number, so this result is shown in the ≥900 category, not as “900, below 900”.
At 900 or above, the label wording (“≥900 mOsm/L must be infused through a central vein”) places the estimate in the ≥900 category [5]. The estimate itself has an error of tens of mOsm in either direction [2], so a borderline value calls for pharmacist review, not a decision from the number alone. Note also that 100 g/L is 10% dextrose, which is above the 5% dextrose figure in the Travasol/Prosol label wording [7, 8].
4. Practice questions
Q1. A PN estimate comes out at 860 mOsm/L. A colleague says “it’s under 900, so it’s safe peripherally.” What’s wrong with that statement?
Answer
The ASPEN 900 mOsm/L recommendation is graded Weak, and ASPEN states that evidence for a safe limit is lacking [1]. The estimate may differ from the measured value [2]. Phlebitis also depends on the osmolar load per hour [13]. And institutional policies differ. The correct statement is “estimated 860 mOsm/L, below the commonly used 900 mOsm/L threshold. Check the local protocol and the pharmacist.”
Q2. Why does adding 250 mL of 20% lipid emulsion to a 1 L PN of 1000 mOsm/L lower its osmolarity?
Answer
20% lipid emulsion itself is only about 260 mOsm/L [5]. Total mOsm = 1000 + (260 × 0.25) = 1065 mOsm in 1.25 L, so 1065 ÷ 1.25 = 852 mOsm/L. The fall comes from dilution with a low-osmolarity fluid. The lipid does not remove osmoles.
Q3. Two peripheral PN regimens have the same osmolarity (800 mOsm/L), but one runs at twice the hourly volume. Based on Timmer and Schipper, which would you expect to cause more phlebitis, and why?
Answer
The faster one. Phlebitis correlated with the osmolarity rate (mOsm infused per hour, r = 0.95) much better than with osmolarity alone (r = 0.37) [13]. Doubling the hourly volume doubles the mOsm per hour.
Q4. A PN contains 15 mEq/L of sodium as sodium phosphate. How much does that contribute using the label-derived factor, and how much using the older teaching value of 3 mOsm/mEq Na?
Answer
Label-derived: 15 × 1.75 = 26.25 ≈ 26 mOsm/L [9]. Teaching value: 15 × 3 = 45 mOsm/L [3]. The difference is 18.75 ≈ 19 mOsm/L, enough to move a borderline estimate across 900. State which factor you used.
Related tools and pages
- IV Fluid Osmolarity (calculated osmolarity of common IV fluids)
- Enteral Formula Osmolality
- Osmolality vs Osmolarity
- How Osmometers Work
- How we check content · Disclaimer
Educational content, not medical advice. These are calculation aids for learning. They are not prescribing, compounding or administration instructions. PN is a high-alert medication [1]. Peripheral vs central decisions follow your institution’s protocols, the product labeling, and your pharmacist or nutrition-support team. Institutional thresholds vary.
References
- Boullata JI, Gilbert K, Sacks G, et al.; A.S.P.E.N. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr. 2014;38(3):334–377. https://pubmed.ncbi.nlm.nih.gov/24531708/ (full text: https://aspenjournals.onlinelibrary.wiley.com/doi/10.1177/0148607114521833)
- Valero Zanuy MA, Pablos Bravo S, Lazaro Cebas A, et al. Agreement between different equations to estimate osmolarity of parenteral nutrition solutions. Nutr Hosp. 2015;32(6):2757–2762. https://pubmed.ncbi.nlm.nih.gov/26667731/
- Cober MP, Tucker AM, Derenski K. Strategies for Successful Parenteral Nutrition Order Writing. ASHP Midyear Clinical Meeting 2016 (slides 16–17, citing Mattox TW et al., Pharmacotherapy 9e, 2014, and the A.S.P.E.N. Core Curricula). https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Clinical-Pharmacy-Resources/Nutrition-Support/2016-MCM/MCM16-335-Strategies-for-Successful-Parenteral-nutrition.pdf
- 5% Dextrose Injection, USP (Baxter). DailyMed, accessed 2026-10-18 (label text: “Revised: 6/2025”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36e9478c-5df0-4b47-b97d-de3626d7cb29
- Intralipid 20% (lipid injectable emulsion) (Fresenius Kabi). DailyMed, accessed 2026-10-17 (label text: “Revised: 8/2025”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e025f1-a38e-4af2-9e18-13ea12977cf5
- Intralipid 30% (pharmacy bulk package) (Fresenius Kabi). DailyMed, accessed 2026-10-17 (label text: “Revised: 8/2025”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98460eae-5195-48d2-ab73-00d276879ef6
- Travasol (amino acids) Injection (Baxter). DailyMed, accessed 2026-10-18 (label text: “Revised: 10/2020”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8543b5be-0f43-4891-9e56-d7c39fe839b5
- Prosol (amino acids) Injection (Baxter). DailyMed, accessed 2026-10-18 (label text: “Revised: 10/2020”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc2ace81-5881-43f1-ba94-41b674adc2fc
- Sodium Phosphates Injection, USP (Hospira). DailyMed, accessed 2026-10-18 (label text: “Revised: 01/2018”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f044d16-295e-43ff-72a3-b045c387bc5c
- Potassium Phosphates Injection, USP (American Regent). DailyMed, accessed 2026-10-18 (label text: “Revised: 2/2025”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a85cca-c463-4f39-9335-177b04c290a9
- Pereira-da-Silva L, Virella D, Henriques G, et al. A simple equation to estimate the osmolarity of neonatal parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 2004;28(1):34–37. https://pubmed.ncbi.nlm.nih.gov/14763792/
- Dugan S, Le J, Jew RK. Maximum tolerated osmolarity for peripheral administration of parenteral nutrition in pediatric patients. JPEN J Parenter Enteral Nutr. 2014;38(7):847–851. https://pubmed.ncbi.nlm.nih.gov/23851423/
- Timmer JG, Schipper HG. Peripheral venous nutrition: the equal relevance of volume load and osmolarity in relation to phlebitis. Clin Nutr. 1991;10(2):71–75. https://pubmed.ncbi.nlm.nih.gov/16839898/
- Sodium Chloride Injection, USP 14.6% (Hospira). DailyMed, accessed 2026-10-18, setid 018a8807-1331-41c3-4889-c7ec502a9043. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=018a8807-1331-41c3-4889-c7ec502a9043
- Potassium Chloride for Injection Concentrate, USP (Hospira). DailyMed, accessed 2026-10-18, setid 559a0a8c-a8fe-40a5-b196-21f9308780ab. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559a0a8c-a8fe-40a5-b196-21f9308780ab
- Sodium Acetate Injection, USP 2 mEq/mL (Hospira). DailyMed, accessed 2026-10-18, setid abc41ed1-9512-4bea-9295-1a9ca134b6c2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abc41ed1-9512-4bea-9295-1a9ca134b6c2
- Potassium Acetate Injection, USP 2 mEq/mL (Hospira). DailyMed, accessed 2026-10-18, setid c58f8112-d587-493a-91b7-2b48c80bb7bf. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c58f8112-d587-493a-91b7-2b48c80bb7bf
- Magnesium Sulfate Injection, USP 50% (Hospira). DailyMed, accessed 2026-10-18 (label text: “Revised: 8/2021”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e175d329-315f-4f3b-bb4c-06ad4e042967
- Potassium Phosphates Injection, USP (Hospira). DailyMed, accessed 2026-10-18 (label text: “Revised: 9/2025”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fcbc814-c7a4-469a-8b1d-6819b961bfb9
- Dextrose Injection 20%, 30%, 40%, 50% and 70% (ICU Medical). DailyMed, accessed 2026-10-18 (label text: “Revised: 11/2018”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5cb7a5a-bbe8-4217-a82e-da818f7771c9
- Calcium Gluconate Injection, pharmacy bulk package (B. Braun). DailyMed, accessed 2026-10-18 (label text: “Revised: 4/2023”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af362bcb-7010-4eb5-b8c4-42aa3b0cdcde
- Aminosyn-PF 10% (amino acids) Injection (ICU Medical). DailyMed, accessed 2026-10-18 (label text: “Revised: August, 2018”). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46e74ce4-cd7e-437f-bf54-ca9b98eb2663
- Calcium Gluconate 10% w/v Injection BP (B. Braun Melsungen). Summary of Product Characteristics, text revised 07/03/2024. electronic medicines compendium (emc), accessed 2026-10-18. https://www.medicines.org.uk/emc/product/15226/smpc
- Calcium Gluconate Injection, USP 10% (Sandoz Canada). Prescribing Information, date of preparation May 13, 2026 (Submission Control No. 299772). Health Canada Drug Product Database, accessed 2026-10-18. https://pdf.hres.ca/dpd_pm/00084720.PDF
- Calcium Gluconate 10% solution for injection/infusion BP (hameln pharma). Summary of Product Characteristics, text revised 13/06/2023. electronic medicines compendium (emc), accessed 2026-10-18. https://www.medicines.org.uk/emc/product/6264/smpc